Hematologic Malignancy
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
CI-CAN-00000765Explore in graph →
Hematologic298 active trials6 approved drugs47 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000765Explore in graph →
Clinical trials
1,406 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (273)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00005803 | Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma | completed | Phase 1 / Phase 2 | 76 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 29, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER |
| 2 |
| Jan 21, 2020 |
| clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT01685892 | A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia | completed | Phase 1 | 82 | Genentech, Inc.INDUSTRY | 2 | Jan 10, 2020 | clinicaltrials |
| NCT00027820 | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | Phase 1 / Phase 2 | 106 | Fred Hutchinson Cancer CenterOTHER | 3 | Dec 20, 2019 | clinicaltrials |
| NCT01732861 | Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma | completed | Phase 1 | 20 | CelgeneINDUSTRY | 2 | Dec 20, 2019 | clinicaltrials |
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT02254772 | A Phase I/II Study of Intratumoral Injection of SD-101 | completed | Phase 1 / Phase 2 | 9 | Robert LowskyOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT00419250 | A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia | completed | Phase 1 | 52 | CelgeneINDUSTRY | 7 | Nov 8, 2019 | clinicaltrials |
| NCT01351935 | Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia | completed | Phase 1 | 113 | CelgeneINDUSTRY | 1 | Nov 8, 2019 | clinicaltrials |
| NCT02006485 | Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies | completed | Phase 1 | 160 | TG Therapeutics, Inc.INDUSTRY | 1 | Nov 5, 2019 | clinicaltrials |
| NCT01013441 | CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia | completed | Phase 1 | 20 | University of PennsylvaniaOTHER | 1 | Oct 23, 2019 | clinicaltrials |
| NCT02100852 | TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 1 | 19 | TG Therapeutics, Inc.INDUSTRY | 1 | Oct 2, 2019 | clinicaltrials |
| NCT01699152 | Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | completed | Phase 1 | 16 | Tragara Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 25, 2019 | clinicaltrials |
| NCT00850057 | Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | completed | Phase 1 | 16 | University of California, San DiegoOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT00634881 | Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 13 | German CLL Study GroupOTHER | 1 | Jun 13, 2019 | clinicaltrials |
| NCT00880815 | Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant | completed | Phase 1 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 3, 2019 | clinicaltrials |
| NCT00697346 | Study of MLN8237 in Participants With Advanced Hematological Malignancies | completed | Phase 1 | 58 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | May 31, 2019 | clinicaltrials |
| NCT00727415 | Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapy(LLC0606) | completed | Phase 1 / Phase 2 | 42 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 22, 2019 | clinicaltrials |
| NCT01634217 | Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation | completed | Phase 1 | 16 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 18, 2019 | clinicaltrials |
| NCT02240719 | Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer | completed | Phase 1 | 20 | University of California, DavisOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT01292603 | A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia | completed | Phase 1 | 240 | Hoffmann-La RocheINDUSTRY | 19 | Dec 19, 2018 | clinicaltrials |
| NCT01306643 | Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma | completed | Phase 1 / Phase 2 | 18 | Gilead SciencesINDUSTRY | 1 | Nov 19, 2018 | clinicaltrials |
| NCT01484015 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia | completed | Phase 1 | 70 | Wake Forest University Health SciencesOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT00001830 | Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants | completed | Phase 1 | 110 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01445132 | Adoptive Cell Therapy for B-Cell Cancers in Patients After Stem Cell Transplantation | completed | Phase 1 | 11 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01517035 | Improving Blood Stem Cell Collection and Transplant Procedures | completed | Phase 1 / Phase 2 | 43 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT02226861 | Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation | completed | Phase 1 | 24 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01129193 | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma | completed | Phase 1 | 44 | Amir MortazaviOTHER | 1 | Jun 4, 2018 | clinicaltrials |
| NCT00504972 | Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies | completed | Phase 1 | 23 | Weill Medical College of Cornell UniversityOTHER | 1 | May 29, 2018 | clinicaltrials |
| NCT01558167 | A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia(CLL2P) | completed | Phase 1 / Phase 2 | 22 | German CLL Study GroupOTHER | 1 | May 15, 2018 | clinicaltrials |
| NCT01567709 | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Apr 11, 2018 | clinicaltrials |
| NCT01030536 | Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL) | completed | Phase 1 / Phase 2 | 23 | MedImmune LLCINDUSTRY | 2 | Apr 9, 2018 | clinicaltrials |
| NCT01832922 | BR in Patients With CLL With Comorbidities and/or Renal Dysfunction | completed | Phase 1 | 8 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Mar 30, 2018 | clinicaltrials |
| NCT01515176 | Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia | completed | Phase 1 / Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Mar 15, 2018 | clinicaltrials |
| NCT01805375 | A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies | completed | Phase 1 | 28 | Cancer Research UKOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT01460134 | A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers | completed | Phase 1 | 90 | Celldex TherapeuticsINDUSTRY | 1 | Jan 31, 2018 | clinicaltrials |
| NCT01400685 | Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL | completed | Phase 1 | 34 | Massachusetts General HospitalOTHER | 1 | Jan 25, 2018 | clinicaltrials |
| NCT00854646 | Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) | completed | Phase 1 | 22 | Traws Pharma, Inc.INDUSTRY | 1 | Jan 10, 2018 | clinicaltrials |
| NCT01534715 | IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | completed | Phase 1 | 49 | ImmunoGen, Inc.INDUSTRY | 2 | Dec 29, 2017 | clinicaltrials |
| NCT01110473 | ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies | completed | Phase 1 | 52 | AbbVie (prior sponsor, Abbott)INDUSTRY | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00466895 | Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia. | completed | Phase 1 | 37 | Leslie AndritsosOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT02132624 | CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial. | completed | Phase 1 / Phase 2 | 15 | Uppsala UniversityOTHER | 1 | Oct 30, 2017 | clinicaltrials |
| NCT01254578 | Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2017 | clinicaltrials |
| NCT01369849 | Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 15 | National Cancer Institute (NCI)NIH | 1 | Sep 15, 2017 | clinicaltrials |
| NCT01399840 | Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies | completed | Phase 1 | 33 | PfizerINDUSTRY | 2 | Sep 15, 2017 | clinicaltrials |
| NCT00281983 | Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia | completed | Phase 1 / Phase 2 | 100 | German CLL Study GroupOTHER | 2 | Jul 24, 2017 | clinicaltrials |
| NCT00058240 | Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00366418 | Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia | completed | Phase 1 | 4 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00614042 | Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma | completed | Phase 1 | 96 | Aptevo TherapeuticsINDUSTRY | 1 | Jun 28, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jan 29, 2020source: clinicaltrials